Fanny Erika Palumbo

9PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyPharmacogenomicsInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 11, 2026
Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Salvatore Perrone, Andrea Corbingi, Calogero Vetro

|Jan 28, 2026
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

Andrea Duminuco, Paola De Luca, Gaia Stanzione

|Jan 13, 2026
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Calogero Vetro, Irene Azzali, Elisabetta Petracci

|Dec 31, 2025
Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.

Arianna Scala, Teresa Angela Trunfio, Chiara Pennisi

|Dec 04, 2025
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Calogero Vetro, Bruno Garibaldi, Francesco Grimaldi

|Oct 31, 2025
Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.

Fanny Erika Palumbo, Calogero Vetro, Cinzia Maugeri

Pageof 2

Frequent Collaborators

9 joint publications

Calogero Vetro

4 joint publications

Lucia Gozzo

3 joint publications

Andrea Duminuco

3 joint publications

Giovanni Marconi